Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

Area of Science:

• Hematology
• Clinical Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is a hematologic malignancy characterized by plasma cell proliferation.
• Relapsed/refractory MM presents significant treatment challenges, necessitating effective salvage therapies.
• Existing salvage options often have limitations in efficacy or tolerability.

Purpose of the Study:

• To evaluate the safety and efficacy of a novel salvage regimen (RMPT) in patients with relapsed/refractory multiple myeloma.
• To determine response rates, progression-free survival (PFS), and overall survival (OS) with RMPT therapy.
• To characterize the adverse event profile associated with the RMPT regimen.

Main Methods:

• Phase II, multicenter, open-label, non-comparative trial design.
• Treatment regimen: Oral lenalidomide, melphalan, prednisone, and thalidomide (RMPT) for six 28-day cycles.
• Maintenance therapy with lenalidomide; aspirin for thromboprophylaxis.

Main Results:

• Overall response rate (ORR) of 75% in 44 enrolled patients with relapsed/refractory MM.
• Subgroup responses included 32% very good partial response (VGPR) and 2% complete response (CR).
• One-year PFS was 51%, and one-year OS was 72%; manageable hematologic and non-hematologic toxicities were observed.

Conclusions:

• The RMPT regimen is an effective salvage therapy for relapsed/refractory multiple myeloma.
• RMPT demonstrates a favorable efficacy profile with manageable adverse events, including low rates of thromboembolic events and peripheral neuropathy.
• These findings support the RMPT regimen as a basis for larger, randomized phase III trials in multiple myeloma.